Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior)...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Osteoporosis |
| Online Access: | http://dx.doi.org/10.1155/2016/8738959 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850211708173287424 |
|---|---|
| author | A. Sánchez L. R. Brun H. Salerni P. R. Costanzo D. González A. Bagur B. Oliveri M. B. Zanchetta V. Farías L. Maffei V. Premrou J. L. Mansur M. S. Larroudé M. A. Sarli P. Rey M. R. Ulla M. M. Pavlove S. Karlsbrum M. L. Brance |
| author_facet | A. Sánchez L. R. Brun H. Salerni P. R. Costanzo D. González A. Bagur B. Oliveri M. B. Zanchetta V. Farías L. Maffei V. Premrou J. L. Mansur M. S. Larroudé M. A. Sarli P. Rey M. R. Ulla M. M. Pavlove S. Karlsbrum M. L. Brance |
| author_sort | A. Sánchez |
| collection | DOAJ |
| description | The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed. |
| format | Article |
| id | doaj-art-8f64e17fc45a48ca99d9dc3d19561208 |
| institution | OA Journals |
| issn | 2090-8059 2042-0064 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Osteoporosis |
| spelling | doaj-art-8f64e17fc45a48ca99d9dc3d195612082025-08-20T02:09:30ZengWileyJournal of Osteoporosis2090-80592042-00642016-01-01201610.1155/2016/87389598738959Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with OsteoporosisA. Sánchez0L. R. Brun1H. Salerni2P. R. Costanzo3D. González4A. Bagur5B. Oliveri6M. B. Zanchetta7V. Farías8L. Maffei9V. Premrou10J. L. Mansur11M. S. Larroudé12M. A. Sarli13P. Rey14M. R. Ulla15M. M. Pavlove16S. Karlsbrum17M. L. Brance18Centro de Endocrinología, Rosario, ArgentinaLaboratorio de Biología Ósea, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, ArgentinaConsultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo (CICEMO), Buenos Aires, ArgentinaConsultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo (CICEMO), Buenos Aires, ArgentinaMautalen Salud e Investigación, Buenos Aires, ArgentinaMautalen Salud e Investigación, Buenos Aires, ArgentinaMautalen Salud e Investigación, Buenos Aires, ArgentinaInstituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Cátedra de Osteología y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, ArgentinaInstituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Cátedra de Osteología y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, ArgentinaConsultorios Asociados de Endocrinología Dra. Laura Maffei, Buenos Aires, ArgentinaConsultorios Asociados de Endocrinología Dra. Laura Maffei, Buenos Aires, ArgentinaCentro de Endocrinología y Osteoporosis, La Plata, ArgentinaHospital Milstein, Buenos Aires, ArgentinaInstituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Cátedra de Osteología y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, ArgentinaInstituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Cátedra de Osteología y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, ArgentinaCentro de Endocrinología y Osteopatías Médicas, Córdoba, ArgentinaHospital Durand, Buenos Aires, ArgentinaHospital Durand, Buenos Aires, ArgentinaCentro de Reumatología, Rosario, ArgentinaThe aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.http://dx.doi.org/10.1155/2016/8738959 |
| spellingShingle | A. Sánchez L. R. Brun H. Salerni P. R. Costanzo D. González A. Bagur B. Oliveri M. B. Zanchetta V. Farías L. Maffei V. Premrou J. L. Mansur M. S. Larroudé M. A. Sarli P. Rey M. R. Ulla M. M. Pavlove S. Karlsbrum M. L. Brance Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis Journal of Osteoporosis |
| title | Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
| title_full | Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
| title_fullStr | Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
| title_full_unstemmed | Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
| title_short | Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
| title_sort | effect of denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis |
| url | http://dx.doi.org/10.1155/2016/8738959 |
| work_keys_str_mv | AT asanchez effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT lrbrun effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT hsalerni effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT prcostanzo effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT dgonzalez effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT abagur effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT boliveri effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT mbzanchetta effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT vfarias effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT lmaffei effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT vpremrou effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT jlmansur effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT mslarroude effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT masarli effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT prey effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT mrulla effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT mmpavlove effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT skarlsbrum effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis AT mlbrance effectofdenosumabonbonemineraldensityandmarkersofboneturnoveramongpostmenopausalwomenwithosteoporosis |